Shopping Cart 0
Cart Subtotal
USD 0

EpiCast Report: Glaucoma-Epidemiology Forecast to 2026

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3995

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7990

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 11985
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

EpiCast Report: Glaucoma-Epidemiology Forecast to 2026

Summary

Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eye'soptic nerve, resulting in progressive, irreversible vision loss. Glaucoma is one of the leading causes of blindness worldwide, especially in elderly people. Glaucoma is generally categorized as open-angle glaucoma (OAG), angle-closure glaucoma (ACG), or secondary glaucoma (SG), though other less common types exist. OAG and ACG can be classified as primary (primary open-angle glaucoma [POAG] or primary angle-closure glaucoma [PACG], respectively) or SG, depending on the cause.

To forecast the total prevalent cases of POAG, PACG, NTG, PPG, and SG in the 7MM, GlobalData epidemiologists selected nationally representative, population-based studies that provided these epidemiological data in the 7MM. GlobalData epidemiologists obtained data for the diagnosed prevalent cases of PPG from primary market research and authentic secondary sources. In addition, the forecast is supported by robust, country-specific data that were obtained from various authentic sources, such as research articles published in peer-reviewed journals.

In the 7MM, the total prevalent cases of POAG will increase from 7,224,135 cases in 2016 to 8,549,547 cases in 2026, at an Annual Growth Rate (AGR) of 1.83%. In the 7MM, the total prevalent cases of PACG will increase from 2,644,012 cases in 2016 to 3,124,740 cases in 2026, at an AGR of 1.82%. GlobalData forecasts that all markets will see an increase in the total prevalent cases and diagnosed prevalent cases of POAG and PACG during the forecast period.

Scope

The Glaucoma EpiCast Report provides an overview of the risk factors and global trends of glaucoma in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of primary open-angle glaucoma (POAG) or primary angle-closure glaucoma (PACG), segmented by sex and age (40-49 years, 50-59 years, 60-69 years, 70-79 years, and ages 80 years and older) in these markets. In addition, this report provides a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of glaucoma clinical types normal-tension glaucoma (NTG), pre perimetric glaucoma (PPG), and secondary glaucoma (SG). The report also includes the diagnosed incident cases of acute PACG.

The glaucoma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

The Glaucoma EpiCast report will allow you to

Develop business strategies by understanding the trends shaping and driving the global glaucoma market.

Quantify patient populations in the global glaucoma market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for glaucoma therapeutics in each of the markets covered.

Understand the population of glaucoma clinical types NTG, PPG, and SG.

READ MORE

Table Of Content

Scope

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.4.3 Total Prevalent Cases of POAG

3.4.4 Total Prevalent Cases of PACG

3.4.5 Total Prevalent Cases of NTG and PPG

3.4.6 Total Prevalent Cases of SG

3.4.7 Diagnosed Prevalent Cases

3.4.8 Diagnosed Incident Cases of Acute PACG

3.5 Epidemiological Forecast for Glaucoma (2016-2026)

3.5.1 Total Prevalent Cases of POAG

3.5.2 Age-Specific Total Prevalent Cases of POAG

3.5.3 Sex-Specific Total Prevalent Cases of POAG

3.5.4 Diagnosed Prevalent Cases of POAG

3.5.5 Total Prevalent Cases of PACG

3.5.6 Age-Specific Total Prevalent Cases of PACG

3.5.7 Sex-Specific Total Prevalent Cases of PACG

3.5.8 Diagnosed Prevalent Cases of PACG

3.5.9 Total Prevalent Cases of NTG

3.5.10 Diagnosed Prevalent Cases of NTG

3.5.11 Total Prevalent Cases of PPG 3

3.5.12 Diagnosed Prevalent Cases of PPG 3

3.5.13 Total Prevalent Cases of SG 3

3.5.14 Diagnosed Prevalent Cases of SG 3

3.5.15 Diagnosed Incident Cases of Acute PACG 3

3.6 Discussion 3

3.6.1 Epidemiological Forecast Insight 3

3.6.2 Limitations of the Analysis 3

3.6.3 Strengths of the Analysis 3

4 Appendix 3

4.1 Bibliography 3

4.2 High-Prescribing Physician Survey

4.3 About the Authors

4.3.1 Epidemiologist

4.3.2 Reviewers

4.3.3 Global Director of Therapy Analysis and Epidemiology

4.3.4 Global Head and EVP of Healthcare Operations and Strategy

4.4 About GlobalData

4.5 Contact Us

4.6 Disclaimer


List Of Figure

1.2 List of Figures

Figure 1: 7MM, Total Prevalent Cases of POAG, Both Sexes, Ages ?40 Years, 2016 and 2026

Figure 2: 7MM, Total Prevalent Cases of PACG, Both Sexes, Ages ?40 Years, 2016 and 2026

Figure 3: 7MM, Age-Standardized Total Prevalence of POAG, Men and Women, Ages ?40 Years, 2016

Figure 4: 7MM, Age-Standardized Total Prevalence of PACG, Men and Women, Ages ?40 Years, 2016

Figure 5: 7MM, Sources Used to Forecast Total Prevalent Cases of POAG

Figure 6: 7MM, Sources Used to Forecast Total Prevalent Cases of PACG

Figure 7: 7MM, Sources Used to Forecast Total Prevalent Cases of NTG

Figure 8: 7MM, Sources Used to Forecast Total Prevalent Cases of PPG

Figure 9: 7MM, Sources Used to Forecast Total Prevalent Cases of SG

Figure 10: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Acute PACG

Figure 11: 7MM, Age-Specific Total Prevalent Cases of POAG, Both Sexes, Ages ?40 Years, N, 2016

Figure 12: 7MM, Sex-Specific Total Prevalent Cases of POAG, Both Sexes, Ages ?40 Years, N, 2016

Figure 13: 7MM, Age-Specific Total Prevalent Cases of PACG, Both Sexes, Ages ?40 Years, N, 2016

Figure 14: 7MM, Sex-Specific Total Prevalent Cases of PACG, Both Sexes, Ages ?40 Years, N, 2016


List Of Table

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for Glaucoma

Table 2: 7MM, Total Prevalent Cases of POAG, Both Sexes, Ages ?40 Years, N, Selected Years 2016-2026

Table 3: 7MM, Diagnosed Prevalent Cases of POAG, Both Sexes, Ages ?40 Years, N, Selected Years 2016-2026

Table 4: 7MM, Total Prevalent Cases of PACG, Both Sexes, Ages ?40 Years, N, Selected Years 2016-2026

Table 5: 7MM, Diagnosed Prevalent Cases of PACG, Both Sexes, Ages ?40 Years, N, Selected Years 2016-2026

Table 6: 7MM, Total Prevalent Cases of NTG, Both Sexes, Ages ?40 Years, N, Selected Years 2016-2026

Table 7: 7MM, Diagnosed Prevalent Cases of NTG, Both Sexes, Ages ?40 Years, N, Selected Years 2016-2026

Table 8: 7MM, Total Prevalent Cases of PPG, Both Sexes, Ages ?40 Years, N, Selected Years 2016-2026

Table 9: 7MM, Diagnosed Prevalent Cases of PPG, Both Sexes, Ages ?40 Years, N, Selected Years 2016-2026

Table 10: 7MM, Total Prevalent Cases of SG, Both Sexes, Ages ?40 Years, N, Selected Years 2016-2026

Table 11: 7MM, Diagnosed Prevalent Cases of SG, Both Sexes, Ages ?40 Years, N, Selected Years 2016-2026

Table 12: 7MM, Diagnosed Incident Cases of Acute PACG, Both Sexes, Ages ?40 Years, N, Selected Years 2016-2026

Table 13: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com